NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 30 Oct 2017 (#39)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **to inform of your intent to apply.***

Timelines:** **Confirm your intent to apply as soon as possible, but not later than 30 days before the submission date. All final documents MUST reach the RGMO seven (7) workdays before NIH application due date. The application will be submitted four (4) workdays before the application due date.

Important Notices:

- **Reminder: FORMS-E Grant Application Forms and Instructions must be used for due dates on or after January 25, 2018 (NOT-OD-18-009)**
- **NIH Plans for Clinical Trial Specific Parent R01 and Parent R21 Funding Opportunity Announcements (NOT-OD-18-010)**
- **Notice of Technical Assistance Webinar for Human Heredity and Health in Africa (H3Africa) RFAs: RFA-RM-17-020, RFA-RM-17-021 (NOT-RM-18-001)**

1. Role of Peripheral Proteostasis on Brain Aging and Alzheimer's Disease (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-AG-18-020) **Type: R01**
Application Due Date: February 9, 2018. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimer's Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.
Budget: NIA intends to commit $5 million in FY 2018 to fund 8-10 awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Immunity in the Elderly (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-AI-17-037) **Type: *R01***
Application Due Date: February 22, 2018. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The goal of this reissued Funding Opportunity Announcement (FOA) is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. Human studies are required, and inclusion of relevant animal studies is permitted for mechanistic understanding. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections and/or vaccinations, including the effects of chronic inflammation on those responses, and applications that will assess changes in immune processes in dental, oral and craniofacial tissues in the elderly.
Budget: The following NIH components intend to commit the following amounts in FY 2019: NIAID, $3.2M, 6-8 awards; NIA, $2M, 4-5 awards and NIDCR, $0.5M, 1 award. Direct costs for each application are expected to be $300,000 or less per year. Budgets should be commensurate with the proposed studies and adequately justified. Scope of the proposed project should determine the project period. The maximum period is 5 years.

3. Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) Clinical Trial Not Allowed

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-408) **Type:** ***R21***

Application Due Date: Standard dates and Standard AIDS dates. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.

4. Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) Clinical Trial Not Allowed

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-409) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. Single-Site Investigator-Initiated Clinical Trials (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-406) **Type:** ***R61/R33***

Application Due Date: *New, and Revision applications:* February 13, 2018; June 13, 2018; October 11, 2018; February 13, 2019; June 13, 2019. *Resubmission applications:* March 13, 2018, July 13, 2018, November 13, 2018, March 13, 2019, July 11, 2019. *Aids applications:* May 14, 2018; September 13; 2018; January 11, 2019; May 13, 2019; September 13, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted in response to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to application submission. Staff will be able to assist applicants in meeting the objectives of this FOA.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the requested project award period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 1 year for the R61 phase and up to 4 years for the R33 phase.

6. Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative) - Clinical Trial Required

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-407) **Type:** ***UG3/UH3***

Application Due Date: *New, and Revision applications:* February 13, 2018; June 13, 2018; October 11, 2018; February 13, 2019; June 13, 2019. *Resubmission applications:* March 13, 2018, July 13, 2018, November 13, 2018, March 13, 2019, July 11, 2019. *Aids applications:* May 14, 2018; September 13; 2018; January 11, 2019; May 13, 2019; September 13, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-18-410). The objective of the Clinical Coordinating Center application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should include plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a Clinical Coordinating Center (CCC) application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined budgets of the CCC and DCC will be used to determine whether the policy regarding direct costs of $500,000 or more in any year will be applied. The scope of the proposed project should determine the requested project award period. The project period for the UG3 phase will be up to 1 year. The project period for the UH3 phase is expected to be 4 years. With strong justification, up to 6 years for the UH3 may be requested.

7. Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-410) **Type:** ***U24***

Application Due Date: *New, and Revision applications:* February 13, 2018; June 13, 2018; October 11, 2018; February 13, 2019; June 13, 2019. *Resubmission applications:* March 13, 2018, July 13, 2018, November 13, 2018, March 13, 2019, July 11, 2019. *Aids applications:* May 14, 2018; September 13; 2018; January 11, 2019; May 13, 2019; September 13, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Clinical Coordinating Center (PAR-18-407). The DCC application must be specific for the clinical trial being proposed in the collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined budgets of the CCC and DCC will be used to determine whether the policy regarding direct costs of $500,000 or more in any year will be applied. The scope of the proposed project should determine the requested project award period. The period of award is expected to be 5 years. Up to 7 years may be requested if strongly justified.

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).